医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japanese Patent Office Grants Broad Claims Covering CRISPR/Cas9 Gene Editing Technology

2018年06月15日 AM09:00
このエントリーをはてなブックマークに追加


 

DUBLIN

ERS Genomics announced today that the Japanese Patent Office has granted Dr. Emmanuelle Charpentier, ERS Genomics’ co-founder, together with the University of California and University of Vienna, its first Japanese patent with broad claims covering the single-guide format of CRISPR/Cas9 technology and uses for gene editing. The claims include compositions and uses in cellular and non-cellular settings, including bacteria, plants, animals, and human cells.

“We are pleased to see the continued recognition of Dr. Charpentier and her colleagues’ contribution to this revolutionary technology,” commented Eric Rhodes, CEO of ERS. “This is a significant milestone in the regional granting of the CRISPR/Cas9 patents and combined with our issued patents in China, Australia, New Zealand, Hong Kong and Singapore provides substantial access in the Asia-Pacific region. ERS is already working closely with Japan-based Summit Pharmaceuticals International to help companies there that want to apply CRISPR/Cas9 technology in their research and commercialization efforts.”

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology: www.ersgenomics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180614006220/en/

CONTACT

ERS Genomics
MacDougall Biomedical Communications
Mario
Brkulj or Kara Mazey
ersgenomics@macbiocom.com
or
Summit
Pharmaceuticals International

Dr. Yoshikazu Ando
yoshikazu.ando@summitpharma.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作